Clinical trials are a fundamental step in the development of new therapies for
treating virtually every medical condition. At Synta Pharmaceuticals, our
clinical research is focused on innovative therapeutic options that can extend
or enhance the lives of patients in the areas of cancer and inflammatory
diseases. All of the drug candidates currently in development at Synta are
derived from our proprietary chemical compound library and reflect our
commitment to truly original research.
Synta places a high priority on sharing information and results regarding our
ongoing and completed clinical studies with the medical community. We have
registered all of our active, company-sponsored clinical trials on the National
Institutes of Health Web site
www.clinicaltrials.gov. This information is available here on our site,
as well.
No Synta drug candidates have been approved by the FDA or any other regulatory
body for the treatment of diseases.
STA - 9090
STA-9090 is a novel, synthetic, injectable, small molecule Hsp90 inhibitor
(inhibits heat shock protein 90 - Hsp90), a chaperone that regulates numerous
proteins that drive proliferation in cancer cells, in particular kinases) with
a novel chemical structure that is unrelated to the Hsp90 inhibitor
geldanamycin or its family of related compounds, such as 17-AAG.
Phase 1 Solid Tumor Trials
Two trials are being conducted: one with a once-weekly dosing schedule, one with
a twice-weekly dosing schedule. The primary objective of both studies is to
identify maximum tolerated dose; secondary objectives are to characterize
safety, tolerability, signs of biologic and clinical activity.
Click here to get more information on our once-weekly trial.
Click
here to get more information on our twice-weekly trial.
Phase 1/2 Trials in Hematologic Malignancies
Two trials are being conducted: one with a once-weekly dosing schedule, one with
a twice-weekly dosing schedule. The primary objective of both studies is to
identify maximum tolerated dose; secondary objectives are to characterize
safety, tolerability, signs of biologic and clinical activity.
Click
here to get more information on our once-weekly trial.
Click
here to get more information on our twice-weekly trial.
Phase 2 Trial in Non-Small Cell Lung Cancer
This trial is an open-label, multi-center, multi-cohort Phase 2 study designed
to characterize the efficacy and safety of STA-9090 in patients with stage IIIB
or IV non-small cell lung cancer, based on a once-weekly dosing schedule.
Patients will be assessed for tumor response based on the RECIST criteria.
Subjects tolerating STA-9090 may continue on treatment until disease
progression.
Click here for more information on this trial.
Phase 2 Trial in Gastrointestinal Stromal Tumors
This trial is an open-label, multi-center Phase 2 study designed to characterize
the efficacy and safety of STA-9090 in patients with metastatic or unresectable
GIST following failure of Gleevec® and Sutent®, based on a once-weekly
intravenous dosing schedule. Patients will be assessed for clinical benefit
rate per RECIST criteria.
Click here for more information on this trial.
Phase 2 Trial in Colorectal Cancer
This is an open-label, investigator-sponsored Phase 2 clinical study being
conducted in patients with advanced colon cancer or rectal cancer.
Click here for more information on this trial.
Phase 2 Trial in Gastric Cancer
This is an open-label, investigator-sponsored Phase 2 clinical study being
conducted in patients with advanced gastric, esophageal, or gastroesophageal
cancers.
Click here for more information on this trial.
[Top of page]
Contact Information:
Synta Pharmaceuticals
45 Hartwell Avenue
Phone 781-541-7125
Fax 781-274-1270
[Top of page]
|
